Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

Benzer Materyaller

• Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study
  Yazar:: Lumry, William R., ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study
  Yazar:: Li, H. Henry, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study
  Yazar:: H. Henry Li, ve diğerleri
  Baskı/Yayın Bilgisi: (2019-08-01)
• Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
  Yazar:: Riedl, Marc A., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies
  Yazar:: Busse, Paula J., ve diğerleri
  Baskı/Yayın Bilgisi: (2018)